Printer Friendly

CAMBRIDGE NEUROSCIENCE, INC. SELLS 225,000 ADDITIONAL SHARES OF COMMON STOCK

                  CAMBRIDGE NEUROSCIENCE, INC. SELLS
               225,000 ADDITIONAL SHARES OF COMMON STOCK
    CAMBRIDGE, Mass., Nov. 13 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) announced today that its underwriters have exercised an over-allotment option to purchase an additional 225,000 shares of common stock in connection with the previously announced public offering of 1.5 million shares of CNSI stock.
    Common stock outstanding after the offering (including the exercise of the over-allotment option) will be 8,616,791.
    Smith Barney, Harris Upham & Co., and Montgomery Securities were the underwriters for the offering.
    Cambridge NeuroScience, Inc. is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceutical products to treat a variety of severe neurological and psychiatric disorders.  The company's product development efforts are focused in three areas: neuroprotective compounds for the treatment of acute neurological disorders such as stroke and traumatic brain injury; novel antipsychotic compounds for the treatment of mental illnesses such as schizophrenia; and growth factors for the treatment of neurodegenerative diseases.
    -0-                    11/13/91
    /CONTACT:  Philip V. Holberton, chief financial officer of Cambridge NeuroScience, Inc., 617-225-0600 or Marcia A. Kean of Feinstein Partners Inc. for Cambridge NeuroScience, 617-577-8110/
    (CNSI) CO:  Cambridge NeuroScience, Inc. ST:  Massachusetts IN:  MTC SU: PB-KM -- NE008 -- 3959 11/13/91 12:46 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1991
Words:211
Previous Article:MAZDA REPORTS 1ST 10-DAY DOMESTIC SALES FOR NOVEMBER 1991
Next Article:CSX TO ACQUIRE SEQUA BARGE UNIT
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE, INC. SELLS 1.5 MILLION SHARES OF COMMON STOCK
CAMBRIDGE NEUROSCIENCE AWARDED ORPHAN DRUG STATUS FOR PRAMIRACETAM; PHASE III TRIALS TO BEGIN IN 1992
CAMBRIDGE NEUROSCIENCE REPORTS THIRD QUARTER AND NINE MONTH FINANCIAL RESULTS
CAMBRIDGE NEUROSCIENCE REPORTS FOURTH QUARTER AND 1991 YEAR-END FINANCIAL RESULTS
CAMBRIDGE NEUROSCIENCE ANNOUNCES $14 MILLION PRIVATE PLACEMENT
CAMBRIDGE NEUROSCIENCE REPORTS THIRD QUARTER 1995 RESULTS
Cambridge NeuroScience Inc. Appoints Director, Marketing to Initiate Marketing Plan for Cerestat(R)
Cambridge NeuroScience Receives Drug Delivery Device Patent for Sustained, Controlled Release of Large Molecules
Cambridge NeuroScience Reports Second Quarter 1998 Financial Results
Cambridge NeuroScience receives two United States patents and three United States patent allowances.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters